Dolmetsch is the president of Tempero Bio, a biotech company seeking to cure substance use disorders, and an adjunct professor at Stanford University.
[citation needed] He obtained a doctorate in neuroscience from Stanford University in 1997 under the supervision of Richard Lewis,[1] where he worked on the role of calcium oscillations in lymphocyte activation.
[2][3] He completed a postdoctoral fellowship with Michael E. Greenberg at Harvard Medical School where he studied excitation-transcription coupling, specifically the role of voltage-gated calcium channels in controlling the activation of transcription factors in neurons.
[5] Dolmetsch led a laboratory at Stanford University from 2002 to 2013 that studied the influence of electrical activity and calcium signals on early brain development.
[citation needed] Dolmetsch's graduate and postdoctoral work established a role for intracellular calcium oscillation frequency and amplitude in regulating transcription in eukaryotic cells.
[citation needed] As the global head of neuroscience at Novartis Institutes for BioMedical Research, he helped create a drug pipeline for neuropsychiatric diseases,[23][24][16] introduced human stem cell models as tools for drug discovery in neuroscience[21][15] and contributed to the development of several treatments for brain disorders that are now in the clinic including Aimovig (erenumab) for migraine and Kesimpta (ofatumumab) for multiple sclerosis.